Q-omics provides the consensus-scored VPS26CP1 profile across patient tissues and cancer cell-line models. VPS26CP1 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, VPS26CP1 is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, VPS26CP1 RNA expression shows 7,459 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight THCA, PRAD, and LAML as cancer lineages where VPS26CP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VPS26CP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VPS26CP1 survival associations across molecular data types. VPS26CP1 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VPS26CP1 RNA expression–survival associations across cancer types. High VPS26CP1 expression shows unfavorable associations in THCA, KICH, BLCA, COAD, SKCM and CESC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for VPS26CP1 RNA expression.
This table summarizes VPS26CP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for VPS26CP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VPS26CP1 shows higher tumor expression in PRAD. The PRAD box plot shows higher VPS26CP1 RNA expression in tumor versus normal tissue (log2 FC = +0.040, t-test p = .009).
This table shows molecular features associated with VPS26CP1 in patient tissues and cancer cell lines. In patient samples, VPS26CP1 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
